KEYNOTE-859 (MK3475-859)

About this trial

This trial is for patients with a type of stomach or gastrooesophageal junction cancer called human epidermal growth factor receptor 2 (HER2) negative adenocarcinoma.

This trial aims to determine the effectiveness of a drug called Pembrolizumab used in combination with chemotherapy in the treatment of previously untreated, HER2 negative, advanced stomach or gastroesophageal junction cancer

Patient Profile

This triaql is open to men and women over 18 years of age with previously untreated HER2 negative advanced cancer of the stomach or gastroesophageal junction

Where’s this trial being run?

Beaumont Hospital, St James’s Hospital, and Tallaght University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: KEYNOTE-859 (MK3475-859)
Number: 18-30
Full Title:

Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma.

Principal Investigator: Maeve Lowery
Type: Industry Sponsored


Recruitment Started: Global: Unknown
Ireland: Feb 2019
Global Recruitment Target: 780
Ireland Recruitment Target: 12